This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy



These resources are designed to provide HCPs with regularly updated background information on key therapy areas in oncology, as well as on afatinib*, nintedanib**, and their pivotal clinical trials. Information is provided in easily digestible and shareable formats.

*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Filter by: